Association of time since pneumococcal polysaccharide vaccine receipt and CD4 count with antibody response to the 13-valent pneumococcal conjugate vaccine in HIV-infected adults

References

• Heffernan RT, Barrett NL, Gallagher KM, Hadler JL, Harrison LH, Reingold AL, Khoshnood K, Holford TR, Schuchat A. Declining incidence of invasive Streptococcus pneumoniae infections among persons with AIDS in an era of highly active antiretroviral therapy, 1995–2000. J Infect Dis 2005; 191:2038-45; PMID:15897989; http://dx.doi.org/10.1086/430356
   PubMed Web of Science ®Google Scholar
• French N, Gordon SB, Mwalukomo T, White SA, Mwafulirwa G, Longwe H, Mwaiponya M, Zijlstra EE, Molyneux ME, Gilks CF. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010; 362:812-22; PMID:20200385; http://dx.doi.org/10.1056/NEJMoa0903029
   PubMed Web of Science ®Google Scholar
• Info.NIH A. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. 2015
   Google Scholar
• (CDC) CfDCaP. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012; 61:816-9; PMID:23051612
   PubMedGoogle Scholar
• Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, van Werkhoven CH, van Deursen AM, Sanders EA, Verheij TJ, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015; 372:1114-25; PMID:25785969; http://dx.doi.org/10.1056/NEJMoa1408544
   PubMed Web of Science ®Google Scholar
• Musher DM, Rueda AM, Nahm MH, Graviss EA, Rodriguez-Barradas MC. Initial and subsequent response to pneumococcal polysaccharide and protein-conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia. J Infect Dis 2008; 198:1019-27; PMID:18710324; http://dx.doi.org/10.1086/591629
   PubMed Web of Science ®Google Scholar
• Miiro G, Kayhty H, Watera C, Tolmie H, Whitworth JA, Gilks CF, French N. Conjugate pneumococcal vaccine in HIV-infected Ugandans and the effect of past receipt of polysaccharide vaccine. J Infect Dis 2005; 192:1801-5; PMID:16235180; http://dx.doi.org/10.1086/497144
   PubMed Web of Science ®Google Scholar
• Crum-Cianflone NF, Huppler Hullsiek K, Roediger M, Ganesan A, Patel S, Landrum ML, Weintrob A, Agan BK, Medina S, Rahkola J, et al. A randomized clinical trial comparing revaccination with pneumococcal conjugate vaccine to polysaccharide vaccine among HIV-infected adults. J Infect Dis 2010; 202:1114-25; PMID:20795819; http://dx.doi.org/10.1086/656147
   PubMed Web of Science ®Google Scholar
• Ahmed F, Steinhoff MC, Rodriguez-Barradas MC, Hamilton RG, Musher DM, Nelson KE. Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: results from a randomized trial. J Infect Dis 1996; 173:83-90; PMID:8537687; http://dx.doi.org/10.1093/infdis/173.1.83
   PubMed Web of Science ®Google Scholar
• Chen M, Ssali F, Mulungi M, Awio P, Yoshimine H, Kuroki R, Furumoto A, Tanimura S, Kityo C, Nagatake T, et al. Induction of opsonophagocytic killing activity with pneumococcal conjugate vaccine in human immunodeficiency virus-infected Ugandan adults. Vaccine 2008; 26:4962-8; PMID:18639599; http://dx.doi.org/10.1016/j.vaccine.2008.06.093
   PubMed Web of Science ®Google Scholar
• Kroon FP, van Dissel JT, Ravensbergen E, Nibbering PH, van Furth R. Enhanced antibody response to pneumococcal polysaccharide vaccine after prior immunization with conjugate pneumococcal vaccine in HIV-infected adults. Vaccine 2000; 19:886-94; PMID:11115712; http://dx.doi.org/10.1016/S0264-410X(00)00232-2
   PubMed Web of Science ®Google Scholar
• O'Brien KL, Hochman M, Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? Lancet Infect Dis 2007; 7:597-606; PMID:17714673; http://dx.doi.org/10.1016/S1473-3099(07)70210-4
   PubMed Web of Science ®Google Scholar
• French N, Nakiyingi J, Carpenter LM, Lugada E, Watera C, Moi K, Moore M, Antvelink D, Mulder D, Janoff EN, et al. Twenty-three-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet 2000; 355:2106-11; PMID:10902624; http://dx.doi.org/10.1016/S0140-6736(00)02377-1
   PubMed Web of Science ®Google Scholar
• Glesby MJ, Watson W, Brinson C, Greenberg RN, Lalezari JP, Skiest D, Sundaraiyer V, Natuk R, Gurtman A, Scott DA, et al. Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine. J Infect Dis 2014; 212(1):18-27
   PubMed Web of Science ®Google Scholar
• MSF. Pneumococcal Conjugate Vaccines (PCV). The Right Shot: Bringing down barriers to affordable and adapted vaccines. Second ed 2015. p. 72-7
   Google Scholar
• Väkeväinen M, Eklund C, Eskola J, Käyhty H. Cross-reactivity of antibodies to type 6B and 6A polysaccharides of Streptococcus pneumoniae, evoked by pneumococcal conjugate vaccines, in infants. J Infect Dis 2001; 184:789-93; http://dx.doi.org/10.1086/322984
   PubMed Web of Science ®Google Scholar
• Nunes MC, Madhi SA. Safety, immunogenicity and efficacy of pneumococcal conjugate vaccine in HIV-infected individuals. Hum Vaccin Immunother 2012; 8:161-73; PMID:22426374; http://dx.doi.org/10.4161/hv.18432
   PubMed Web of Science ®Google Scholar
• Siegrist C-A. Vaccine immunology. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 6th ed. China: Elsevier Saunders; 2013. p. 14-32
   Google Scholar
• Klugman K, Black S, Dagan R, Malley R, Whitney C. Pneumococcal conjugate vaccine and pneumococcal common protein vaccines. In: Plotkin O, and Offit., editor. Vaccines. China: Elsevier Saunders; 2013. p. 504-41
   Google Scholar
• Lopes VB, Hassing RJ, de Vries-Sluijs TE, El Barzouhi A, Hansen BE, Schutten M, de Man RA, van der Ende ME. Long-term response rates of successful hepatitis B vaccination in HIV-infected patients. Vaccine 2013; 31:1040-4; PMID:23273969; http://dx.doi.org/10.1016/j.vaccine.2012.12.047
   PubMed Web of Science ®Google Scholar
• Abzug MJ, Song LY, Levin MJ, Nachman SA, Borkowsky W, Pelton SI, International Maternal Pediatric Adolescent AIDS Clinical Trials Group P1024 and P1061s Protocol Teams. Antibody persistence and immunologic memory after sequential pneumococcal conjugate and polysaccharide vaccination in HIV-infected children on highly active antiretroviral therapy. Vaccine 2013; 31:4782-90; PMID:23954381; http://dx.doi.org/10.1016/j.vaccine.2013.08.002
   PubMed Web of Science ®Google Scholar
• Bhorat AE, Madhi SA, Laudat F, Sundaraiyer V, Gurtman A, Jansen KU, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination. AIDS. 2015; 29(11):1345-54; PMID:25888646
   PubMed Web of Science ®Google Scholar
• Nahm MH, Goldblatt David. Training manual for Enzyme linked immunosorbent assay for the quantitation of Streptococcus pneumoniae serotype specific IgG (Pn PS ELISA). (007sp Version). World Health Organization Pneumococcal Serology Reference Laboratories: WHO; 2015. Available at http://www.vaccine.uab.edu/ELISAProtocol(007sp).pdf.
   Google Scholar
• Richter SS, Heilmann KP, Dohrn CL, Riahi F, Diekema DJ, Doern GV. Pneumococcal serotypes before and after introduction of conjugate vaccines, United States, 1999–2011(1.). Emerg Infect Dis 2013; 19:1074-83; PMID:23763847; http://dx.doi.org/10.3201/eid1907.121830
   PubMed Web of Science ®Google Scholar